CAS: 7554-65-6; 4-Methyl-1H-Pyrazole

相似化合物

56010-88-9 121669-69-0 31108-57-3

上下游产品

CAS号10602-37-6 1,1,3,3-四乙氧基-2-甲基丙烷 | CAS号82231-51-4 4-甲基吡唑-3-甲酸 | CAS号37718-11-9 1H-吡唑-4-甲酸 | CAS号1072-68-0 1,4-二甲基吡唑 | CAS号14766-43-9 1-苯基-4-甲基吡唑 | CAS号857641-45-3 2-(4-METHYL-1H-... | CAS号38858-90-1 4-甲基-3-硝基-1H-吡唑 | CAS号1246853-06-4 4-methyl-3,5-di...

1,1,3,3-四乙氧基-2-甲基丙烷 以84的收率获得产物4-甲基吡唑
参考文献:Ultrapure 4-Methylpyrazole
标题:Ultrapure 4-Methylpyrazole
摘要:本发明涉及一种超纯的4-甲基吡唑,其中含有少于0.1%的吡唑,并且每种含量少于10 Ppm的肼和硝基苯甲醛.通过一种新的工艺制备超纯的4-甲基吡唑,以使乙基乙烯醚的存在量少于0.01%.

专利信息

专利号:US-5191087-A
优先权日:1991-07-24
标 题 :Process for the synthesis of 1,4-disubstituted pyrazoles
发明人：ALCARAZ JEAN-MARIE; LECACHEUR MARYSE; ROBIN YVES
权利人:POUDRES & EXPLOSIFS STE NALE
摘要:The present invention relates to a process for the synthesis of 1,4-disubstituted pyrazoles. A monosubstituted hydrazine is reacted with the product of reaction of an acetal with an N-substituted halomethyliminium salt, preferably N,N-dimethylchloromethyliminium chloride. n The 1,4-disubstituted pyrazoles are, in particular, important intermediates in the synthesis of herbicides or drugs.

专利号:WO-2024137329-A1
优先权日:2022-12-20
标 题:Methods for the synthesis of complement factor d inhibitors and intermediates thereof
发明人：HASHIMOTO AKIHIRO; TIPPARAJU SURESH KUMAR
权利人:ALEXION PHARMA INC
摘要:The present disclosure provides methods for the synthesis of complement factor D inhibitors and intermediates thereof.

专利号:US-11530204-B2
优先权日:2019-09-30
标 题 :Biocatalytic synthesis of cryptophycin anticancer agents
发明人：SHERMAN DAVID H; SCHMIDT JENNIFER J
权利人:UNIV MICHIGAN REGENTS
摘要:The disclosure provides cryptophycin intermediates, cryptophycin analogs, and cryptophycin chimeric molecules useful in treating cancer, as well as methods of producing these compounds and methods of treating cancer.

专利号:US-9901901-B2
优先权日:2012-05-21
标 题 :Selective extraction of anions from solution
发明人：MEZEI GELLERT
权利人:WESTERN MICHIGAN UNIV RESEARCH FOUNDATION; THE BOARD OF TRUSTEES OF WESTERN MICHIGAN UNIV
摘要:A method of selectively extracting anions from an aqueous solution using an anion encapsulating aggregate formed upon the addition of a solvent, a copper contributor, a hydroxide contributor, a counterion contributor, and pyrazole to an aqueous solution containing the anions, or upon the addition of a solvent, a polymeric chain of [Cu II (μ-OH)(μ-pz)] ∞ and a counterion contributor to the aqueous solution. The aggregates include compounds of the formula cis Cu II x (OR 1 ) y (R 2 pz) z , where R 1 is H or an alkyl group, R 2 is H, or an alkyl group or a charged group, pz is pyrazolate and each of x, y, and z is an integer between about 1 and about 40. In addition, ligand-containing anion encapsulating aggregates can be formed by synthesis with a lig-and-bound pyrazole or by substituting the ligand-bound pyrazole for the pyrazole incorporated in the aggregate.

专利号:WO-2023287345-A1
优先权日:2021-07-16
标 题 :Aqueous solid phase peptide synthesis
发明人：PAWLAS JAN; LUDEMANN-HOMBOURGER OLIVIER
权利人:POLYPEPTIDE LABORATORIES HOLDING PPL AB
摘要:The present invention relates to a solid phase peptide synthesis (SPPS) where the coupling of amino acids is performed in an aqueous solution comprising at least one organic co-solvent miscible with water. The aqueous solution is capable of sufficiently solubilize the activated Fmoc-α-amine protected amino acid or activated Fmoc-α-amine protected peptide fragment, and where the resin is capable of swelling in the presence of the aqueous solution above about 4 mLg-1. The invention also encompasses a method for regeneration of spent aqueous solution from the SPPS.

专利号:US-10226449-B2
优先权日:2013-12-20
标 题:Heterocyclic modulators of lipid synthesis and combinations thereof
发明人：HEUER TIMOTHY SEAN; OSLOB JOHAN D; MCDOWELL ROBERT S; JOHNSON RUSSELL; YANG HANBIAO; EVANCHIK MARC; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W; DUKE GREGORY; OHOL-GUPTA YAMINI; O'FARRELL MARIE
权利人:3 V BIOSCIENCES INC
摘要:Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.